482 related articles for article (PubMed ID: 23726266)
21. [Expression and clinical significance of plasma small RNA in patients with pancreatic cancer].
Pan W; Tang W; Yuan W; Yu Q; Zuo W; Xu C; Ma J
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):351-4. PubMed ID: 25030590
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer.
Martens-Uzunova ES; Jalava SE; Dits NF; van Leenders GJ; Møller S; Trapman J; Bangma CH; Litman T; Visakorpi T; Jenster G
Oncogene; 2012 Feb; 31(8):978-91. PubMed ID: 21765474
[TBL] [Abstract][Full Text] [Related]
23. Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients.
March-Villalba JA; Martínez-Jabaloyas JM; Herrero MJ; Santamaría J; Aliño SF; Dasí F
Expert Opin Biol Ther; 2012 Jun; 12 Suppl 1():S69-77. PubMed ID: 22559196
[TBL] [Abstract][Full Text] [Related]
24. Quantitative multi-gene expression profiling of primary prostate cancer.
Schmidt U; Fuessel S; Koch R; Baretton GB; Lohse A; Tomasetti S; Unversucht S; Froehner M; Wirth MP; Meye A
Prostate; 2006 Oct; 66(14):1521-34. PubMed ID: 16921506
[TBL] [Abstract][Full Text] [Related]
25. [Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction].
Tao ZH; Mao XL; Wang CH; Chen XD; Yu KY; Weng ZL; Hu YP; Zhang XH; Xie H; Wang OC; Song QT; Li CD; Chen ZG
Zhonghua Nan Ke Xue; 2007 Feb; 13(2):130-3. PubMed ID: 17345768
[TBL] [Abstract][Full Text] [Related]
26. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection.
Payne SR; Serth J; Schostak M; Kamradt J; Strauss A; Thelen P; Model F; Day JK; Liebenberg V; Morotti A; Yamamura S; Lograsso J; Sledziewski A; Semjonow A
Prostate; 2009 Sep; 69(12):1257-69. PubMed ID: 19459176
[TBL] [Abstract][Full Text] [Related]
27. [Quantitative detection of differential display code 3 mRNA in peripheral blood of patients with prostate cancer].
Weng ZL; Yu KY; Mao XL; Tao ZH; Chen XD; Wu XL; Hu YP; Wang SQ; Li CD; Chen ZG
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(41):2911-5. PubMed ID: 17288789
[TBL] [Abstract][Full Text] [Related]
28. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
29. Molecular phenotyping of circulating tumour cells in patients with prostate cancer: prediction of distant metastases.
Giesing M; Driesel G; Molitor D; Suchy B
BJU Int; 2012 Dec; 110(11 Pt C):E1202-11. PubMed ID: 23046102
[TBL] [Abstract][Full Text] [Related]
30. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.
Avgeris M; Stravodimos K; Scorilas A
Prostate; 2011 Dec; 71(16):1780-9. PubMed ID: 21520157
[TBL] [Abstract][Full Text] [Related]
31. Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.
Salonia A; Gallina A; Briganti A; Zanni G; Suardi N; Capitanio U; Colombo R; Bertini R; Freschi M; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2011 Apr; 107(8):1243-9. PubMed ID: 20883480
[TBL] [Abstract][Full Text] [Related]
32. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.
de Kok JB; Verhaegh GW; Roelofs RW; Hessels D; Kiemeney LA; Aalders TW; Swinkels DW; Schalken JA
Cancer Res; 2002 May; 62(9):2695-8. PubMed ID: 11980670
[TBL] [Abstract][Full Text] [Related]
33. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
[TBL] [Abstract][Full Text] [Related]
34. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
35. The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer.
Ke D; Li H; Zhang Y; An Y; Fu H; Fang X; Zheng X
Oncotarget; 2017 Mar; 8(13):21516-21525. PubMed ID: 28423525
[TBL] [Abstract][Full Text] [Related]
36. Elevated serum-circulating RNA in patients with conventional renal cell cancer.
Feng G; Li G; Gentil-Perret A; Tostain J; Genin C
Anticancer Res; 2008; 28(1A):321-6. PubMed ID: 18383864
[TBL] [Abstract][Full Text] [Related]
37. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.
Cao DL; Ye DW; Zhang HL; Zhu Y; Wang YX; Yao XD
Prostate; 2011 May; 71(7):700-10. PubMed ID: 20957673
[TBL] [Abstract][Full Text] [Related]
38. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting.
Adam A; Engelbrecht MJ; Bornman MS; Manda SO; Moshokoa E; Feilat RA
BJU Int; 2011 Dec; 108(11):1728-33. PubMed ID: 21507188
[TBL] [Abstract][Full Text] [Related]
39. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma.
Fang C; Zhu DX; Dong HJ; Zhou ZJ; Wang YH; Liu L; Fan L; Miao KR; Liu P; Xu W; Li JY
Ann Hematol; 2012 Apr; 91(4):553-9. PubMed ID: 21987025
[TBL] [Abstract][Full Text] [Related]
40. Molecular PCA3 diagnostics on prostatic fluid.
van Gils MP; Cornel EB; Hessels D; Peelen WP; Witjes JA; Mulders PF; Rittenhouse HG; Schalken JA
Prostate; 2007 Jun; 67(8):881-7. PubMed ID: 17440939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
